PPARA and metabolic dysfunction-associated steatotic liver disease: In a rat model of NAFLD, the most common chronic liver disease in western countries, HT (10 mg/kg/day) significantly corrected the metabolic impairment induced by HFD, increasing hepatic peroxisome proliferator activated receptor PPAR-α and its downstream-regulated gene fibroblast growth factor 21, the phosphorylation of acetyl-CoA carboxylase [156].